Sunitinib

Sunitinib is an oral, small-molecule tyrosine kinase inhibitor used as a targeted therapy for several types of cancer. It functions by inhibiting multiple receptor tyrosine kinases involved in tumor growth, angiogenesis, and metastatic progression. The drug is marketed under the brand name Sutent by Pfizer and has become a standard treatment option in specific oncological settings following pivotal clinical trials.

Medical uses

Sunitinib is approved for the treatment of advanced renal cell carcinoma, a common type of kidney cancer, where it is used as a first-line therapy. It is also indicated for gastrointestinal stromal tumor after disease progression on or intolerance to imatinib therapy. Additionally, it is used in advanced, well-differentiated pancreatic neuroendocrine tumors that are unresectable, locally advanced, or metastatic. Its use is typically guided by oncologists within frameworks established by organizations like the National Comprehensive Cancer Network and the European Medicines Agency.

Adverse effects

Common adverse effects include fatigue, diarrhea, nausea, mucositis, and distinctive skin discoloration or yellowing. More serious potential effects involve cardiotoxicity, such as left ventricular dysfunction and hypertension, requiring monitoring by cardiologists. Other significant risks include hypothyroidism, hematologic abnormalities like neutropenia and thrombocytopenia, and rare cases of hepatic impairment or posterior reversible encephalopathy syndrome. Management often involves dose modifications and supportive care protocols.

Pharmacology

Sunitinib acts as a multi-targeted inhibitor of several receptor tyrosine kinases, including vascular endothelial growth factor receptor, platelet-derived growth factor receptor, KIT, and FLT3. By blocking these signaling pathways, it inhibits angiogenesis and tumor cell proliferation. The drug is metabolized primarily by the hepatic enzyme CYP3A4, and its pharmacokinetics can be affected by strong inducers or inhibitors of this system, such as rifampin or ketoconazole. Its active metabolite, formed via N-dealkylation, contributes significantly to its overall pharmacologic activity.

History

Sunitinib was discovered by scientists at Sugen, a biotechnology company later acquired by Pharmacia & Upjohn, which itself became part of Pfizer. Its development was based on research into signal transduction inhibitors for cancer. Key clinical trials, including a pivotal Phase III trial in metastatic renal cell carcinoma, demonstrated superior progression-free survival compared to interferon-alpha. It received its initial approval from the U.S. Food and Drug Administration in 2006 for advanced renal cell carcinoma and gastrointestinal stromal tumor, with subsequent approvals from other agencies like the European Commission.

Society and culture

As a high-cost cancer therapy, sunitinib has been a subject of discussions regarding healthcare economics and drug pricing. It is included on the World Health Organization Model List of Essential Medicines for specific cancers. The drug has been featured in media reports by outlets like The New York Times concerning access to innovative oncology treatments. Legal aspects include patent protections held by Pfizer, with litigation occurring in various jurisdictions, and it has been part of formularies for major insurers and programs like Medicare.

Category:Antineoplastic drugs Category:Tyrosine kinase inhibitors Category:Pfiler